IGLS provides advanced genetic testing services for reproductive medicine, offering accurate and reliable diagnostic information to IVF centers and healthcare institutions. Their services utilize state-of-the-art technologies to support specialists in reproductive care.
Funding
Funding not disclosed
Founders
Product
Problem
In reproductive medicine, accurate and comprehensive genetic testing is crucial for assessing fertility, embryo health, and pregnancy risks. Traditional methods may lack the sensitivity or scope to detect all relevant genetic factors impacting reproductive success.
Solution
IGLS provides a suite of advanced genetic and immunological testing services designed to improve outcomes in assisted reproductive technology (ART). Their offerings include preconception carrier screening, preimplantation genetic testing (PGT), endometrial receptivity analysis, and non-invasive prenatal testing (NIPT). By employing cutting-edge technologies and rigorous quality control, IGLS delivers precise diagnostic information to IVF centers, specialists, and hospitals. These insights enable clinicians to personalize treatment plans, select viable embryos, and minimize the risk of pregnancy complications, ultimately increasing the chances of a successful pregnancy.
Target Audience
IGLS primarily serves IVF centers, reproductive endocrinologists, and hospitals specializing in assisted reproductive technologies.
Features
- SpermXpression®: Test for male infertility.
- WOMAM®: Test to assess the risk of spontaneous abortion and thrombosis.
- ER Map®: Endometrial receptivity analysis to determine the optimal timing for embryo transfer.
- MicroBioMap®: Endometrial microbiota analysis to evaluate the uterine microbial environment.
- IM Map®: Immunological mapping of the endometrium.
- Queendom®: Endometrial studies with a single sample.
- PGT-A: Preimplantation genetic testing for aneuploidies.
- KIR
- HLA-C: Genotyping test for immunological compatibility.
- SafeBaby®: Non-invasive prenatal testing.